<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Comparative Effectiveness Versus Personalized Medicine</title>
	<atom:link href="http://blog.pharmtech.com/2009/10/28/comparative-effectiveness-versus-personalized-medicine/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com/2009/10/28/comparative-effectiveness-versus-personalized-medicine/</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Thu, 09 May 2013 23:30:55 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: cliffintokyo</title>
		<link>http://blog.pharmtech.com/2009/10/28/comparative-effectiveness-versus-personalized-medicine/comment-page-1/#comment-22268</link>
		<dc:creator>cliffintokyo</dc:creator>
		<pubDate>Thu, 29 Oct 2009 07:53:21 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=1965#comment-22268</guid>
		<description>Good article, although &quot;drug companies have come to grips with the notion that the days of the one-pill-fits-all blockbusters are mostly behind them&quot; is not really borne out by the situation on the ground; we still have plenty of billion dollar suits-all drugs.
Comparative effectiveness is a particularly acute issue for countries where docs can only use the drugs that their MoH has approved, further restricting their ability to provide the most suitable treatment for each patient.</description>
		<content:encoded><![CDATA[<p>Good article, although &#8220;drug companies have come to grips with the notion that the days of the one-pill-fits-all blockbusters are mostly behind them&#8221; is not really borne out by the situation on the ground; we still have plenty of billion dollar suits-all drugs.<br />
Comparative effectiveness is a particularly acute issue for countries where docs can only use the drugs that their MoH has approved, further restricting their ability to provide the most suitable treatment for each patient.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
